Seres Therapeutics (FRA:1S9) FCF Yield % : -119.95 (As of Mar. 23, 2025)

View and export this data going back to 2015. Start your Free Trial

What is Seres Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Seres Therapeutics's Trailing 12-Month Free Cash Flow is €-138.13 Mil, and Market Cap is €113.84 Mil. Therefore, Seres Therapeutics's FCF Yield % for today is -119.95%.

The historical rank and industry rank for Seres Therapeutics's FCF Yield % or its related term are showing as below:

FRA:1S9' s FCF Yield % Range Over the Past 10 Years
Min: -125.28 Med: -22.9 Max: 10.68
Current: -119.95

During the past 13 years, the highest FCF Yield % of Seres Therapeutics was 10.68%. The lowest was -125.28%. And the median was -22.90%.

FRA:1S9's FCF Yield % is ranked worse than
85.81% of 1501 companies
in the Biotechnology industry
Industry Median: -14.39 vs FRA:1S9: -119.95

Seres Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

Seres Therapeutics FCF Yield % Historical Data

The historical data trend for Seres Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seres Therapeutics FCF Yield % Chart

Seres Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Yield %

Get a 7-Day Free Trial

-4.32

-0.37

-34.85

-68.63

-91.44

Seres Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Yield %	Get a 7-Day Free Trial															-105.97	-122.53	-135.69	-81.61	-95.67

Competitive Comparison of Seres Therapeutics's FCF Yield %

For the Biotechnology subindustry, Seres Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Seres Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seres Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Seres Therapeutics's FCF Yield % falls into.

Seres Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Seres Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-142.285	/	155.6033952
	=	-91.44%

Seres Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-37.218	*	4	/	155.6033952
	=	-95.67%

Seres Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Seres Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Seres Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Seres Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seres Therapeutics Inc (FRA:1S9) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

MCRB:USA 1S9:Germany

Address

101 Cambridgepark Drive, Cambridge, MA, USA, 02140

Website

https://www.serestherapeutics.com

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Seres Therapeutics Headlines

No Headlines